<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098433</url>
  </required_header>
  <id_info>
    <org_study_id>HM20005777</org_study_id>
    <nct_id>NCT03098433</nct_id>
  </id_info>
  <brief_title>Acute Effects of Liothyronine in Single Administration</brief_title>
  <official_title>Effects of Liothyronine on Energy Expenditure and Cardiovascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the short term effects of a single dose of liothyronine on the
      cardiovascular system and energy expenditure
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double blind, crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>five hours</time_frame>
    <description>Stroke volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>five hours</time_frame>
    <description>Kcal</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Liothyronine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single dose of lithyronine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive a single dose of levothyroxine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will receive a single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Liothyronine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;20&lt;30 kg/m2

          -  TSH &gt;0.5&lt;5.0 mcIU/mL

          -  Negative TPO antibodies

        Exclusion Criteria:

          -  Pregnancy

          -  Use of prescription drugs

          -  Diabetes mellitus

          -  Coronary artery disease

          -  Hypertension

          -  Anemia

          -  Renal insufficiency

          -  Liver disease or ALT &gt;2.5 x the upper laboratory reference limit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco S Celi, MD, MHSc.</last_name>
    <phone>804-828-9696</phone>
    <email>francesco.celi@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvatore Carbone</last_name>
    <email>salvatore.carbone@vcuhealth.org</email>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>March 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
